1,785 results on '"*CHRONIC inflammatory demyelinating polyradiculoneuropathy"'
Search Results
2. A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE)
- Published
- 2024
3. Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
- Author
-
Anthony J. Windebank, Professor of Neurology
- Published
- 2024
4. Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf) (CIDP echo-nerf)
- Published
- 2024
5. Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (GEARCIDP)
- Published
- 2024
6. Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Published
- 2024
7. Patient‐reported daily functioning after SARS‐CoV‐2 vaccinations in autoimmune neuromuscular diseases.
- Author
-
Dam, Koos P. J., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y. L., Kooi, Anneke J., Raaphorst, Joost, Beek, Diederik, Verschuuren, Jan J. G. M., Ruiter, Annabel M., Brusse, Esther, Doorn, Pieter A., Baars, Adája E., Pol, W. Ludo, Goedee, H. Stephan, Brinke, Anja, Ham, S. Marieke, Rispens, Theo, Kuijpers, Taco W., and Eftimov, Filip
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *MOTOR neuron diseases , *NEUROMUSCULAR diseases , *IDIOPATHIC diseases , *CLINICAL deterioration - Abstract
Background and purpose Methods Results Conclusions There are concerns for safety regarding SARS‐CoV‐2 vaccines for patients with autoimmune neuromuscular disease. We compared daily functioning using disease‐specific patient‐reported outcome measures (PROMs) before and after SARS‐CoV‐2 vaccinations.In this substudy of a prospective observational cohort study (Target‐to‐B!), patients with myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and idiopathic inflammatory myopathy (IIM) vaccinated against SARS‐CoV‐2 were included. Surveys of daily functioning (Myasthenia Gravis Activities of Daily Living, Inflammatory Rasch‐Built Overall Disability Scale, Multifocal Motor Neuropathy Rasch‐Built Overall Disability Scale, and Health Assessment Questionnaire–Disability Index) were sent before first vaccination and every 60 days thereafter for up to 12 months. Regression models were constructed to assess differences in PROM scores related to vaccination, compared to scores unrelated to vaccination. We also assessed the proportion of patients with deterioration of at least the minimal clinically important difference (MCID) between before first vaccination and 60 days thereafter.We included 325 patients (median age = 59 years, interquartile range = 47–67, 156 [48%] female sex), of whom 137 (42%) had MG, 79 (24%) had CIDP, 43 (13%) had MMN, and 66 (20%) had IIM. PROM scores related to vaccination did not differ from scores unrelated to vaccination. In paired PROMs, MCID for deterioration was observed in three of 49 (6%) MG patients, of whom none reported a treatment change. In CIDP, MCID for deterioration was observed in eight of 29 patients (28%), of whom two of eight (25%) reported a treatment change.SARS‐CoV‐2 vaccination had no effect on daily functioning in patients with autoimmune neuromuscular diseases, confirming its safety in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Effects of oral steroid sparing immunosuppressive drugs in long term maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
- Author
-
Sajjad, Ali, Hameed, Sajid, and Khan, Sara
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *PLASMA exchange (Therapeutics) , *DRUG dosage , *INTRAVENOUS immunoglobulins , *IMMUNOSUPPRESSIVE agents - Abstract
Background and objectives: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired treatable autoimmune disorder. Due to limited availability and affordability of IV immunoglobulins and therapeutic plasma exchange in Pakistan, oral immunosuppressive drugs (ISDs) are used despite limited role in literature. The study aimed to determine the response to ISDs in CIDP patients by assessing the frequency of remission, reduction of disability using a neuropathy related disability score called Inflammatory Neuropathy Cause and Treatment score (or INCAT score), as well as reduction in steroid maintenance dose. Methods: The retrospective observational study of six months duration (May to October, 2020) was carried out in Aga Khan University Hospital, Karachi, Pakistan. Medical record of all the patients with idiopathic CIDP taking oral ISDs in last five years was selected which included bio-data, clinical signs and symptoms, medication details, and INCAT scores. Descriptive statistics were described i.e. frequency, percentages, mean/standard deviation using Microsoft Excel v.2021. Results: Out of thirteen patients, Azathioprine was used in nine, Mycophenolate mofetil in two and Cyclosporine in two, with remission (INCAT score improvement ≥ 1) achieved in eight, one and zero patients respectively. Duration of ISDs ranged from three to twenty-four months (average 15.8 months). Patients with monoclonal paraproteinemia and prior exposure to ISDs had a poor response to the introduction of subsequent ISDs. Conclusion: The study describes preliminary experience of the potential role of relatively cheaper and more convenient oral ISDs (especially Azathioprine) as an alternative or sparing agent to first line agents for CIDP and sets the stage for larger scale studies and randomized controlled trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
- Author
-
Quint, Paula, Schroeter, Christina B., Kohle, Felix, Öztürk, Menekse, Meisel, Andreas, Tamburrino, Giuliano, Mausberg, Anne K., Szepanowski, Fabian, Afzali, Ali Maisam, Fischer, Katinka, Nelke, Christopher, Räuber, Saskia, Voth, Jan, Masanneck, Lars, Willison, Alice, Vogelsang, Anna, Hemmer, Bernhard, Berthele, Achim, Schroeter, Michael, and Hartung, Hans-Peter
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NERVE conduction studies , *PERIPHERAL neuropathy , *ALCOHOLISM , *TREATMENT effectiveness - Abstract
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory disease affecting the peripheral nerves and the most frequent autoimmune polyneuropathy. Given the lack of established biomarkers or risk factors for the development of CIDP and patients' treatment response, this research effort seeks to identify potential clinical factors that may influence disease progression and overall treatment efficacy. Methods: In this multicenter, retrospective analysis, we have screened 197 CIDP patients who presented to the University Hospitals in Düsseldorf, Berlin, Cologne, Essen, Magdeburg and Munich between 2018 and 2022. We utilized the respective hospital information system and examined baseline data with clinical examination, medical letters, laboratory results, antibody status, nerve conduction studies, imaging and biopsy findings. Aside from clinical baseline data, we analyzed treatment outcomes using the Standard of Care (SOC) definition, as well as a comparison of an early (within the first 12 months after manifestation) versus late (more than 12 months after manifestation) onset of therapy. Results: In terms of treatment, most patients received intravenous immunoglobulin (56%) or prednisolone (39%) as their first therapy. Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score. SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence. Conclusion: Timely diagnosis, prompt initiation of treatment and careful monitoring of treatment response are essential for the prevention of long-term disability in CIDP and suggest a "hit hard and early" treatment paradigm. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Efgartigimod as a novel FcRn inhibitor for autoimmune disease.
- Author
-
Yang, Yun, Shen, Zhengxuan, Shi, Fan, Wang, Fei, and Wen, Ning
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *STIFF-person syndrome , *FC receptors , *IMMUNOGLOBULIN G , *CLINICAL medicine , *MYASTHENIA gravis , *AUTOIMMUNE diseases - Abstract
Immunoglobulin G (IgG) autoantibodies can lead to the formation of autoimmune diseases through Fab and/or Fc-mediated interactions with host molecules as well as activated T cells. The neonatal Fc receptor (FcRn) binds at acidic pH IgG and albumin, and the mechanism for prolonging serum IgG half-life is making IgG re-entry into circulation by prompting it not to be degraded by lysosomes and back to the cell surface. Given the FcRn receptor's essential role in IgG homeostasis, one of the strategies to promote the quick degradation of endogenous IgG is to suppress the function of FcRn, which is beneficial to the treatment of IgG-driven autoimmune disorders like myasthenia gravis (MG), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), stiff person syndrome, and immune thrombocytopenia (ITP). We elaborately read the literature about efgartigimod and systematically reviewed the research progress and clinical application of this novel FcRn inhibitor in autoimmune diseases. Efgartigimod is the firstly FcRn antagonist developed and was approved on 17 December 2021 by the United States for the therapy of acetylcholine receptor-positive MG. In January 2022, efgartigimod received its second regulatory approval in Japan. In addition, the market authorization application in Europe was submitted and validated in August 2021. China's National Medical Products Administration officially accepted the marketing application of efgartigimod on July 13, 2022. To suppress the function of FcRn, which is beneficial to the treatment of IgG-driven autoimmune disorders like MG, CIDP, ITP, and stiff person syndrome. We review the rationale, clinical evidence, and future perspectives of efgartigimod for the treatment of autoimmune disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Unilateral Upper‐Limb Tremor Due to C6 Radiculopathy and Demyelinating Neuropathy.
- Author
-
Nagaratnam, Sai A., Harinesan, Nimalan, Silsby, Matthew, and Fung, Victor S.C.
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NERVE conduction studies , *MOVEMENT disorders , *MOTOR neuron diseases , *MOTOR unit , *POLYNEUROPATHIES , *TREMOR - Abstract
This article presents a case study of a patient with unilateral upper-limb tremor caused by C6 radiculopathy and demyelinating neuropathy. The patient experienced left-arm tremor triggered by left-elbow flexion and reported numbness in the lateral three digits of the left hand. Treatment with intravenous immunoglobulin and onabotulinumtoxinA injections improved neuropathy symptoms and tremor. The article explores the relationship between physiological tremor and muscle shortening, as well as the presence of upper-limb tremor in demyelinating neuropathies. The authors suggest that impaired sensory feedback and abnormal peripheral nerve conduction may contribute to the generation of tremors in these cases. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
12. The difference in nerve ultrasound and motor nerve conduction studies between autoimmune nodopathy and chronic inflammatory demyelinating polyneuropathy.
- Author
-
Niu, Jingwen, Ding, Qingyun, Zhang, Lei, Hu, Nan, Cui, Liying, and Liu, Mingsheng
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NERVE conduction studies , *ULNAR nerve , *BRACHIAL plexus , *MEDIAN nerve - Abstract
Introduction/Aims Methods Results Discussion Nerve enlargement has been described in autoimmune nodopathy and chronic inflammatory demyelinating polyneuropathy (CIDP). However, comparisons of the distribution of enlargement between autoimmune nodopathy and CIDP have not been well characterized. To fill this gap, we explored differences in the ultrasonographic and electrophysiological features between autoimmune nodopathy and CIDP.Between March 2015 and June 2023, patients fulfilling diagnostic criteria for CIDP were enrolled; among them, those with positive antibodies against nodal–paranodal cell‐adhesion molecules were distinguished as autoimmune nodopathy. Nerve ultrasound and nerve conduction studies (NCS) were performed.Overall, 114 CIDP patients and 13 patients with autoimmune nodopathy were recruited. Cross‐sectional areas (CSA) at all sites were larger in patients with CIDP and autoimmune nodopathy than in healthy controls. CSAs at the roots and trunks of the brachial plexus were significantly larger in patients with anti‐neurofascin‐155 (NF155), anti‐contactin‐1 (CNTN1), and anti‐contactin‐associated protein 1 (CASPR1) antibodies than in CIDP patients. The patients with anti‐NF186 antibody did not have enlargement in the brachial plexus. NCS showed more frequent probable conduction block at Erb's point in autoimmune nodopathy than in CIDP (61.9% vs. 36.6% for median nerve, 52.4% vs. 39.5% for ulnar nerve). Markedly prolonged distal motor latencies were also present in autoimmune nodopathy.Patients with autoimmune nodopathies had distinct distributions of peripheral nerve enlargement revealed by ultrasound, as well as distinct NCS patterns, which were different from CIDP. This suggests the potential utility of nerve ultrasound and NCS to supplement clinical characteristics for distinguishing nodopathies from CIDP. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Robot-assisted gait training in patients with various neurological diseases: A mixed methods feasibility study.
- Author
-
Hotz, Isabella, Mildner, Sarah, Stampfer-Kountchev, Michaela, Slamik, Bianca, Blättner, Christoph, Türtscher, Elisabeth, Kübler, Franziska, Höfer, Clemens, Panzl, Johanna, Rücker, Michael, Brenneis, Christian, and Seebacher, Barbara
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *MOTOR neuron diseases , *PATIENT-professional relations , *NEUROLOGICAL disorders , *PARKINSON'S disease , *POLYNEUROPATHIES - Abstract
Background: Walking impairment represents a relevant symptom in patients with neurological diseases often compromising social participation. Currently, mixed methods studies on robot-assisted gait training (RAGT) in patients with rare neurological diseases are lacking. This study aimed to explore the feasibility, acceptability, goal attainment and preliminary effects of RAGT in patients with common and rare neurological diseases and understand the intervention context and process. Methods: A mixed-methods feasibility study was conducted at an Austrian rehabilitation centre. Twenty-eight inpatients after stroke in the subacute and chronic phases, with multiple sclerosis, Parkinson's disease, spinal cord injury, spinocerebellar ataxia, acute/chronic inflammatory demyelinating polyneuropathy and motor neuron disease were included. Patients received RAGT for 45 minutes, 4x/week, for 4 weeks. Baseline and post-intervention assessments included gait parameters, walking and balance, and questionnaires. Semi-structured observations were conducted twice during the intervention period and analysed using thematic analysis. Descriptive statistics within the respective disease groups and calculation of effect sizes for the total sample were performed. Triangulation was employed to develop a deeper understanding of the research topic. Results: Data from 26 patients (mean age 61.6 years [standard deviation 13.2]) were analysed. RAGT was highly accepted by patients and feasible, indicated by recruitment, retention, and adherence rates of 84.8% (95% confidence interval, CI 0.7–0.9), 92.2% (95% CI 0.7–1.0) and 94.0% (95% CI 91.4–96.2), respectively. Goal attainment was high, and only mild adverse events occurred. Improvements in walking speed (10-Metre Walk Test, effect size r = 0.876), walking distance (6-Minute Walk Test, r = 0.877), functional mobility (Timed Up and Go, r = 0.875), gait distance (r = 0.829) and number of steps (r = 0.834) were observed. Four themes were identified: familiarising with RAGT; enjoyment and acceptance through a trusting therapeutic relationship; actively interacting; and minimising dissatisfaction. Discussion: Sufficiently powered randomised controlled trials are needed to validate our results. Trial registration: German Clinical Trials Register, DRKS00027887. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Case report: Chronic inflammatory demyelinating polyneuropathy superimposed on Charcot-Marie-tooth type 1A disease after SARS-CoV-2 vaccination and COVID-19 infection.
- Author
-
Da Li, Hu Yu, Min Zhou, Weinv Fan, Qiongfeng Guan, and Li Li
- Subjects
SARS-CoV-2 ,CHRONIC inflammatory demyelinating polyradiculoneuropathy ,COVID-19 ,MYELIN proteins ,CHARCOT-Marie-Tooth disease ,POLYNEUROPATHIES - Abstract
Background: There is growing evidence that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) or COVID-19 infection is associated with the development of immune mediated neuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP), but the impact of SARS-CoV-2 vaccination and COVID-19 infection on genetic disorders such as Charcot-MarieTooth (CMT) remains unclear. Case presentation: A 42-year-old male with occulted CMT neuropathy type lA (CMT1A) who developed limb numbness and weakness after the second SARSCoV-2-vaccination was confirmed by identifying characteristic repeats in the p11.2 region of chromosome 17. Due to the progressive deterioration of muscle strength over 8weeks, limb atrophy, moderately elevated protein counts in the cerebrospinal fluid, and significant improvement with intravenous human immunoglobulin, which were characteristic of acquired inflammatory neuropathies, he was eventually diagnosed with CIDP superimposed on CMT1A. However, after a three-month plateau, the patient contracted COVID-19, which led to repeated and worsening symptoms of limb weakness and atrophy, thus was diagnosed with a recurrence of CIDP and treated with Intravenous immunoglobulin and methylprednisolone 500mg/d for 5 consecutive days, followed by oral prednisone and mycophenolate mofetil tablets. On 2month follow-up, he exhibited remarkable clinical improvement and could walk independently with rocking gait. After 1year of follow-up, the patient's condition was stable without further change. Conclusion: Our case indicates that CMT1A can deteriorate after SARS-CoV-2 vaccination. Thus, SARS-CoV-2 vaccination should be considered a potential predisposing factor for CMT1A worsening. The possible superposition of CMTIA and CIDP in the context of SARS-CoV-2 infection or immunity suggests that any clinical exacerbation in patients with CMT1A should be carefully evaluated to rule out treatable superposition inflammation. In addition, electrophysiological and imaging examination of the proximal nerves, such as the axillary nerve, is helpful for the diagnosis of CIDP. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Usefulness of somatosensory evoked potentials for monitoring the clinical course of patients with chronic inflammatory demyelinating polyradiculoneuropathy.
- Author
-
Llauradó, A., Gratacòs‐Viñola, M., Vidal‐Taboada, J. M., Sanchez‐Tejerina, D., Salvadó, M., Sotoca, J., López‐Diego, V., Alemañ, J., Restrepo‐Vera, J. L., Lainez, E., Seoane, J. L., Raguer, N., and Juntas‐Morales, R.
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *SOMATOSENSORY evoked potentials , *FISHER exact test , *EUROPEAN integration , *PERIPHERAL nervous system - Abstract
Introduction/Aims Methods Results Discussion Somatosensory evoked potentials (SSEPs) are described as a supportive tool to diagnose chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); however, there is a lack of studies determining the effectiveness of SSEPs in monitoring the clinical course of individuals with this condition. The aims of this study are to evaluate the utility of SSEPs in monitoring patients with CIDP and to assess their association with clinical outcomes following immunomodulatory therapy.This was a single‐center retrospective observational study that included patients who met European Federation of Neurological Societies and Peripheral Nerve Society criteria for CIDP between 2018 and 2023. SSEPs were performed at diagnosis and during follow‐up after the start of immunomodulatory treatment. Fisher's exact test was employed to assess the association between clinical improvement and SSEP improvement.Eighteen patients were included in the study. Ten patients had a typical CIDP pattern and 11 were male. In 17, SSEPs were abnormal prior to the start of immunomodulatory treatment. In patients who showed clinical improvement with immunomodulatory therapy, we observed that 15/17 had partial or complete improvement in SSEPs. Patients who showed no clinical improvement with first‐line treatment exhibited worsening SSEPs. There was a significant association between clinical and SSEPs improvement (p = 0.009).We observed a positive association between improvement in SSEPs and clinical improvement in patients with CIDP. Our data suggest that SSEPs may be useful for monitoring the clinical course of patients with CIDP, but additional, larger studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Successful treatment of relapsed and refractory CIDP with ofatumumab: a first case report.
- Author
-
Jian Wang and QunHong Xiang
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,ORAL drug administration ,TREATMENT effectiveness ,SUBCUTANEOUS injections ,DEMYELINATION - Abstract
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but treatable immune-mediated neuropathy. Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody that has shown promising efficacy in central demyelinating diseases, such as multiple sclerosis (MS). However, there is a lack of studies on the usage of OFA in peripheral demyelinating diseases, particularly CIDP. A case of relapsed and refractory CIDP with an ineffective response to conventional immunotherapy and intolerance to rituximab (RTX) but a positive response to subcutaneous injections of OFA is presented. Case presentation: The patient, a 46-year-old man diagnosed with CIDP, received high-dose intravenous methylprednisolone, intravenous immunoglobulin (IVIG), and plasma exchange(PE) during the acute phase of the disease, and long-term oral administration of prednisone, azathioprine (AZA), and mycophenolate mofetil (MMF) during the remission phase. However, the patient suffered six relapses over a five-year period, and because of these, along with an ineffective response to conventional immunotherapy, and intolerance to RTX, subcutaneous injections of OFA were selected as a prophylactic treatment against relapses. After a total of six injections of OFA, CD19+B cells were substantially depleted. The patient has been followed for more than 23 months without relapse. Conclusions: This case demonstrates the effectiveness and good tolerability of OFA in the treatment of relapsed and refractory CIDP. Further studies are needed to investigate the efficacy and safety of OFA in patients with relapsed and refractory CIDP, especially in those who have shown an ineffective response to conventional immunotherapy and are intolerant to RTX. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies.
- Author
-
Klimas, Rafael, Kordes, Anna, Huckemann, Sophie, Gasz, Zornitsa, Philipps, Jörg, Sgodzai, Melissa, Grüter, Thomas, Sevindik, Melis, Schneider-Gold, Christiane, Gold, Ralf, Keyvani, Kathy, Yoon, Min-Suk, Fisse, Anna Lena, Pitarokoili, Kalliopi, and Motte, Jeremias
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NERVE conduction studies , *ACTION potentials , *INTRAVENOUS immunoglobulins , *PROGNOSIS - Abstract
Introduction: The value of a sural nerve biopsy for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is controversial. Evidence-based recommendations for its implementation are lacking. We investigated factors leading to biopsy and analyzed biopsy outcomes and consequences, assessed the predictability of biopsy outcomes through clinical parameters to avoid unnecessary biopsies, and compared results with electrophysiological and clinical severity to determine their prognostic value. Methods: 190 sural nerve biopsies were analyzed in two cohorts. One consisted of 163 biopsies and the second of 72 biopsies from the prospective Immune-mediated Neuropathies Biomaterial and Data registry (INHIBIT). Both have an intersection of 45 patients. 75 data sets from patients without biopsy were used. Analysis of nerve conduction studies, treatment, overall disability sum score (ODSS), biopsy outcomes, and diagnosis was performed. Results: 51% of biopsied patients received the diagnosis CIDP (77% fulfilled EFNS/PNS criteria), 21% were not CIDP typical, and 27% were unspecific. Biopsied patients responded less frequently to immunotherapies at time of biopsy than non-biopsied patients (p = 0.003). Immunotherapy was initiated more frequently after biopsy (p < 0.001) and more often with intravenous immunoglobulins (p < 0.0001). 76% of all biopsied patients met the electrophysiological criteria for CIDP. Sensory nerve action potential amplitudes of 0 µV still provide 73% of histological diagnostic value. Histologic signs of degeneration predicted ODSS worsening after 1 year (p = 0.028) but disease severity did not correlate with histological damage severity. Discussion: The main indication for nerve biopsy was the treatment of refractory cases of autoimmune neuropathies with the therapeutic consequence of treatment initiation or escalation. Sural biopsy also provided prognostic information. Even with extinguished sural SNAP, the biopsy can still have diagnostic value. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
- Author
-
Zhang, Lijie, Zhang, Yuanyuan, Li, Runyun, Zhu, Jiting, Lin, Aiyu, Yan, Yaping, Zhang, Zaiqiang, Wang, Ning, Xu, Guorong, and Fu, Ying
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *T helper cells , *B cells , *GUILLAIN-Barre syndrome , *IMMUNE response , *POLYNEUROPATHIES - Abstract
Background: To investigate Ranvier's autoantibodies prevalence and isotypes in various peripheral neuropathy variants, compare clinical features between seronegative and seropositive patients, and elucidate immune mechanisms underlying antibody generation. Methods: Antibodies against anti-neurofascin-155 (NF155), NF186, contactin-1 (CNTN1), CNTN2, contactin-associated protein 1 (CASPR1), and CASPR2 were identified through cell-based assays. Plasma cytokines were analyzed in anti-NF155 antibody-positive chronic inflammatory demyelinating polyneuropathy (NF155+ CIDP) and Ranvier's antibodies-negative CIDP (Ab− CIDP) patients using a multiplexed fluorescent immunoassay, validated in vitro in a cell culture model. Results: In 368 plasma samples, 50 Ranvier's autoantibodies were found in 45 individuals, primarily in CIDP cases (25 out of 69 patients) and in 10 out of 122 Guillain-Barré syndrome patients. Anti-NF155 and CNTN1-IgG were exclusive to CIDP. Fourteen samples were NF155-IgG, primarily IgG4 subclass, linked to CIDP features including early onset, tremor, sensory disturbance, elevated CSF protein, prolonged motor latency, conduction block, and poor treatment response. NF155-IgG had low sensitivity (20.28%) but high specificity (100%) for CIDP, rising to 88.88% with tremor and prolonged motor latency. Cytokine profiling in NF155+ CIDP revealed distinct immune responses involving helper T cells, toll-like receptor pathways. Some NF155+ CIDP patients had circulating NF155-specific B cells producing NF155-IgG without antigen presence, suggesting therapeutic potential. Conclusion: The study emphasizes the high specificity and sensitivity of NF155-IgG for diagnosing CIDP characterized by distinctive features. Further investigation into circulating NF155-specific B cell phenotypes may pave the way for B cell directed therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. A pathologically expanded, clonal lineage of IL-21--producing CD4+ T cells drives inflammatory neuropathy.
- Author
-
Seyedsadr, Maryamsadat, Bang, Madison F., McCarthy, Ethan C., Zhang, Shirley, Chen, Ho-Chung, Mohebbi, Mahnia, Hugo, Willy, Whitmire, Jason K., Lechner, Melissa G., and Su, Maureen A.
- Subjects
- *
T cells , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *CD4 antigen , *T cell receptors , *CELL populations , *POLYNEUROPATHIES , *CXCR4 receptors , *SCIATIC nerve injuries - Abstract
Inflammatory neuropathies, which include chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain Barré syndrome (GBS), result from autoimmune destruction of the PNS and are characterized by progressive weakness and sensory loss. CD4+ T cells play a key role in the autoimmune destruction of the PNS. Yet, key properties of pathogenic CD4+ T cells remain incompletely understood. Here, we used paired single-cell RNA-Seq (scRNA-Seq) and single-cell T cell receptor--sequencing (scTCR-Seq) of peripheral nerves from an inflammatory neuropathy mouse model to identify IL-21-- expressing CD4+ T cells that were clonally expanded and multifunctional. These IL-21--expressing CD4+ T cells consisted of 2 transcriptionally distinct expanded cell populations, which expressed genes associated with T follicular helper (Tfh) and T peripheral helper (Tph) cell subsets. Remarkably, TCR clonotypes were shared between these 2 IL-21--expressing cell populations, suggesting a common lineage differentiation pathway. Finally, we demonstrated that IL-21 receptor--KO (IL-21R--KO) mice were protected from neuropathy development and had decreased immune infiltration into peripheral nerves. IL-21 signaling upregulated CXCR6, a chemokine receptor that promotes CD4+ T cell localization in peripheral nerves. Together, these findings point to IL-21 signaling, Tfh/Tph differentiation, and CXCR6-mediated cellular localization as potential therapeutic targets in inflammatory neuropathies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Chronic inflammatory demyelinating polyneuropathy. A case description.
- Author
-
Ariana, Garcia‐Castillo María
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *VISUAL evoked potentials , *CENTRAL nervous system , *INTRAVENOUS immunoglobulins , *POLYNEUROPATHIES , *DEMYELINATION - Abstract
Key Clinical Message: Patients affected by chronic inflammatory demyelinating polyradiculoneuropathy require close follow up due to the neuronal demyelination along with axonal degeneration associated with the disease process, giving the opportunity to the medical team of adequating therapeutics and other medical interventions, according to the evolution of the symptoms, to prevent irreversible axonal degeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Chronic inflammatory demyelinating polyneuropathy following COVID-19 vaccination: a case report and literature review.
- Author
-
Bahramy, Mohammad Ali, Hashempour, Zahra, and Shahriarirad, Reza
- Subjects
- *
POLYNEUROPATHIES , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *LITERATURE reviews , *COVID-19 vaccines , *COVID-19 pandemic , *VACCINATION complications - Abstract
Background: Severe post-vaccination neurological complications are rare. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated polyneuropathy affecting the peripheral nerve roots, which is not well described as a post-vaccination side effect. Here, we present a rare complication of vaccination against SARS-CoV-2, reaching a diagnosis of CIDP. Case presentation: A 67-year-old diabetic male presented with lower extremity paresthesia and weakness following the third dose of the Sinopharm (BBIBP-CorV) vaccine. Despite initial dismissal as a diabetic complication, symptoms escalated, affecting all extremities. Electromyography study revealed abnormal spontaneous activity with chronic reinnervation changes, which was more significant in the lower extremities. Based on the clinical course, radiographic imaging, and laboratory data, a diagnosis of CIDP with severe axonal demyelinating features was established. Treatment with intravenous immunoglobulin (IVIg), prednisolone, and azathioprine resulted in marked improvement of the upper extremities but limited recovery in distal lower extremity muscles. Conclusion: Although CIDP is a rare complication following COVID-19 vaccination, it should be considered in the differential diagnosis. Timely diagnosis of vaccine-induced CIDP is challenging, and any delay can adversely affect treatment response in affected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. A rare presentation of acute-onset chronic inflammatory demyelinating polyneuropathy with the detection of anti-GM3 and anti-sulfatides antibodies: a case report.
- Author
-
Ruohan Sun, Yao Meng, Lingyu Li, Wei-hong Chen, Jing Xu, Peiyuan Lv, and Yanhong Dong
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,INTRAVENOUS immunoglobulins ,GUILLAIN-Barre syndrome ,DEMYELINATION ,PERIPHERAL nervous system ,POLYNEUROPATHIES - Abstract
Objectives: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy defined by clinical progression for more than 2 months. 16-20% of CIDP patients may present with rapidly progressive weakness that resembles GBS, known as acute-onset CIDP (A-CIDP). However, it is challenging to distinguish from GBS-TRF because of their similar clinical symptom and features. In this case review, we report a patient with A-CIDP with the detection of anti-GM3 and anti-sulfatides antibodies, which rarely have been in A-CIDP and may account for her progressive and recurrent symptoms. Methods: We analyzed existing medical literature and described a clinical case of A-CIDP with antibodies positive. Results: We reported a 56-year-old female presented with bilateral lower extremity weakness and distal numbness. She experienced similar symptoms four times and responded well to the IVIg therapy. Lumbar puncture demonstrated albumin-cytologic dissociation and EDX examination revealed multiple peripheral nerve damage. After ruling out other demyelination diseases, a diagnosis of A-CIDP was made. Discussion: The antiganglioside and anti-sulfatide antibodies are involved in CIDP pathogenesis and can help to distinguish A-CIDP and other variants. To prevent secondary damage, it is important to monitor relapse and remission symptoms along the treatment line. A rare case of A-CIDP is discussed concerning the detection of anti-GM3 and anti-sulfatides antibodies, thus making a retrospective comparison of antibodies in some literature to understand A-CIDP better. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort.
- Author
-
Rajabally, Yusuf A., Min, Young Gi, Nazeer, Kabir K., and Englezou, Christina
- Subjects
- *
POLYNEUROPATHIES , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *TERMINATION of treatment - Abstract
Background and purpose Methods Results Conclusions The amplitude, timing, and determinants of improvement with available treatments are uncertain in chronic inflammatory demyelinating polyneuropathy (CIDP). Our primary objective was to quantify categorized outcomes with routine care.We retrospectively studied treatment response within 36 months from initiation in 112 consecutive subjects with CIDP. Response was classified into a proposed new "CIDP treatment‐response category" (CT‐RC), based on achieved endpoints. Determinants of the CT‐RC, of timing of maximum improvement, and of treatment discontinuation were ascertained.The CT‐RC demonstrated high concurrent validity with current outcome measures. Thirty‐six subjects (32.1%) achieved a “complete response,” 37 (33%) a “good partial response,” 10 (8.9%) a “moderate partial response,” and 15 (13.4%) a “poor partial response.” Fourteen subjects (12.5%) were “nonresponsive.” The CT‐RC was independently predicted only by age. Mean time to maximum improvement was 12.1 months (range = 1–36) and was not associated with any pretreatment covariate. Treatment discontinuation occurred in 24 of 62 (38.2%) partial responders and was only associated with shorter pretreatment disease duration. Nonresponders were older and received a similar number of treatments compared to responders.CT‐RC classification indicates persistent disability in >60% of treatment responders in CIDP. Timing of maximum improvement is variable, frequently delayed, and unpredictable. Treatment withdrawal without deterioration is achievable in approximately 40% of subjects and may be more likely with prompt treatment. Treatment withdrawal in partial responders and limited escalation in nonresponders suggest implication of physician‐ and patient‐related factors in suboptimal response. More effective treatments/treatment methods and better understanding of other factors influencing response are needed in CIDP. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Proteinuria is a key to suspect autoimmune nodopathies.
- Author
-
Funakoshi, Kei, Kokubun, Norito, Suzuki, Keisuke, and Yuki, Nobuhiro
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *PROTEINURIA , *ENZYME-linked immunosorbent assay - Abstract
Background and purpose Methods Results Conclusions Reports of patients who have autoimmune nodopathies concurrent with nephrotic syndrome are increasing. We investigated whether proteinuria could be a biomarker of autoimmune nodopathies.Qualitative urinalysis results were retrospectively obtained from 69 patients who were diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) at a hospital in Japan. Proteinuria was graded as mild to severe (i.e., mild, 30–99; moderate, 100–299; severe, 300 mg/dL or more) according to the results of the urine dipstick test. Autoantibodies against the paranodal proteins contactin 1 (CNTN1), neurofascin 155 (NF155), and contactin‐associated protein 1 (Caspr1) and the nodal protein neurofascin 186 (NF186) were measured, and the predominant IgG subclass was determined by enzyme‐linked immunosorbent assay in sera from the 69 patients.Four patients (6%), five patients (7%), and one (1%) patient were positive for anti‐CNTN1, anti‐NF155, and anti‐Caspr1 IgG4 antibodies, respectively. No patients had IgG4 antibodies against NF186. Proteinuria of mild or greater levels was found in three patients with anti‐CNTN1 IgG4 and two patients with anti‐NF155 IgG4 antibodies. The autoantibody‐positive patients more frequently had proteinuria of mild or greater levels than the seronegative patients (p = 0.01).Proteinuria is a possible biomarker of autoimmune nodopathies associated with autoantibodies targeting CNTN1 or NF155. Urinalysis results should be carefully checked for quick differentiation of autoimmune nodopathies from CIDP. Patients who present with nephrotic syndrome should be tested for anti‐CNTN1 IgG4 antibodies, and patients who exhibit mild proteinuria should be tested for anti‐NF155 IgG4 antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Treatment response in patients with clinical and supportive laboratory features of chronic inflammatory demyelinating polyneuropathy without demyelinative findings on nerve conduction studies: A retrospective study.
- Author
-
Curry, Patrick, Herrmann, David N., Stanton, Michael, Mongiovi, Phillip, Akmyradov, Chary, and Logigian, Eric
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *POLYNEUROPATHIES , *NERVE conduction studies , *MAGNETIC resonance imaging , *LUMBOSACRAL plexus , *PATHOLOGICAL laboratories - Abstract
Introduction/Aims Methods Results Discussion Not all patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have evidence of demyelination on nerve conduction studies (NCS). Patients with “supportive” evidence of CIDP on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), ultrasound (US), or nerve biopsy but not on NCS, often receive immunomodulating therapy. We evaluated the treatment response of patients with clinical and supportive features of CIDP lacking NCS evidence of demyelination.Retrospective chart review was conducted on 232 patients who met CIDP clinical criteria and were treated with disease‐modifying therapy. Patients included did not have NCS criteria of demyelination, but did have supportive CSF, MRI, or US findings consistent with CIDP. A positive treatment response was defined as at least a one‐point improvement in the modified Rankin scale (mRS), or a four‐point increase in the Medical Research Council sum score (MRCSS).Twenty patients met criteria: 17 of the 18 (94%) patients with CSF protein >45 mg/dL, 6 of the 14 (43%) with MRI lumbosacral root or plexus enhancement, and 4 of the 6 (67%) with enlarged proximal nerves on US. Eighteen patients received intravenous immunoglobulin, 10 corticosteroids, one plasma exchange, and six other immunomodulatory therapies. Twelve patients had a positive treatment response on the MRCSS or mRS. The presence of MRI lumbosacral root or plexus enhancement was associated with a positive treatment response.A trial of immunomodulating treatment should be considered for patients with clinical features of CIDP in the absence of NCS evidence of demyelination, particularly when there is MRI lumbosacral root or plexus enhancement. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Antiganglioside antibody frequency in routine clinical care settings.
- Author
-
Giesche, Niklas, Böhm‐Gonzalez, Samuel Tobias, Kleiser, Benedict, Kowarik, Markus C., Dubois, Evelyn, Stransky, Elke, Armbruster, Marcel, Grimm, Alexander, and Marquetand, Justus
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *CLINICAL medicine , *MOTOR neuron diseases , *GUILLAIN-Barre syndrome , *CEREBROSPINAL fluid - Abstract
Background and purpose: Antiganglioside antibodies (AGAs) might be involved in the etiopathogenesis of many neurological diseases, such as Miller–Fisher syndrome (MFS) and Guillain–Barré syndrome (GBS). Available comprehensive reference data regarding AGA positivity rates and cross‐responsiveness among AGAs (where one line immunoblot is positive for ≥1 AGA) during routine clinical care are scant. Methods: In this 10‐year monocentric retrospective study, 3560 immunoglobulin (Ig) G and IgM line blots (GA Generic Assays' Anti‐Ganglioside Dot kit) obtained using cerebrospinal fluid (CSF) and serum samples from 1342 patients were analyzed for AGA positivity in terms of 14 diagnosis categories and AGA cross‐responsiveness. Results: Of all 3560 line blots 158 (4.4%) and of all CSF samples 0.4% (4/924) CSF line blots were AGA positive. For serum IgG, blots with positivity rates higher than the standard deviation of 15.6% were associated with MFS (GD3, GD1a, GT1a and GQ1b) and acute motor axonal neuropathy (AMAN) (GM1, GD1a and GT1a). For serum IgM, blots with positivity rates higher than the standard deviation of 8.1% were associated with AMAN (GM2, GT1a and GQ1b), MFS (GM1, GT1a and GQ1b), multifocal motor neuropathy (MMN) (GM1, GM2 and GQ1b) and chronic inflammatory demyelinating polyneuropathy (CIDP) (GM1). Cross‐responsiveness was observed in 39.6% of all positive serum AGA. Conclusions: Testing for AGAs during routine clinical care rarely led to positive findings, both in serum and even less in CSF, except for the diagnoses AMAN, MFS, MMN and CIDP. Nonspecific findings found as cross‐responsiveness between different AGA samples occur frequently, impacting the positivity of most AGA subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
- Author
-
Matthys, Arthur, Bardel, Benjamin, Le Bras, Fabien, Créange, Alain, Nordine, Tarik, Gounot, Romain, Ingen‐Housz‐Oro, Saskia, Carvalho, Muriel, Lefaucheur, Jean‐Pascal, Haioun, Corinne, Planté‐Bordeneuve, Violaine, and Gendre, Thierry
- Subjects
- *
POLYNEUROPATHIES , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *PERIPHERAL neuropathy , *MUSCLE weakness , *GAIT disorders , *PERIPHERAL nervous system - Abstract
Background and purpose: Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV‐induced neuropathy (BV‐CN) is a mild distal sensory axonal polyneuropathy. Severe BV‐induced inflammatory neuropathies (BV‐IN) have been described. BV‐IN contribute to lymphoma‐associated morbidity but might be immunotherapy‐responsive. Our primary objective was to evaluate the rate of BV‐IN. Our secondary objectives were to determine risk factors and warning signs. Methods: We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV‐induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV‐IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV‐CN. Results: Among 83 patients, 41 (49%) developed neuropathy: 35 BV‐CN and 6 BV‐IN. Thus, the rate of BV‐IN was 7.2%. Compared to patients with BV‐CN, no predisposing factor was identified. However, patients with BV‐IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV‐IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy. Conclusions: Brentuximab vedotin‐induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non‐neurologist physicians that care for BV‐treated patients to detect BV‐IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy.
- Author
-
Wieske, Luuk, Michael, Milou R., in ’t Veld, Sjors G. J. G., Visser, Allerdien, van Schaik, Ivo N., Eftimov, Filip, and Teunissen, Charlotte E.
- Subjects
POLYNEUROPATHIES ,CHRONIC inflammatory demyelinating polyradiculoneuropathy ,CHRONIC diseases ,BIOMARKERS ,CELL adhesion molecules ,PATTERN perception receptors - Published
- 2024
- Full Text
- View/download PDF
29. Animal models of immune-mediated demyelinating polyneuropathies.
- Author
-
Ubogu, Eroboghene E.
- Subjects
- *
AUTOIMMUNE diseases , *POLYNEUROPATHIES , *NEURITIS , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *PERIPHERAL nervous system , *ANIMAL models in research - Abstract
Immune-mediated demyelinating polyneuropathies (IMDPs) are rare disorders in which dysregulated adaptive immune responses cause peripheral nerve demyelinating inflammation and axonal injury in susceptible individuals. Despite significant advances in understanding IMDP pathogenesis guided by patient data and representative mammalian models, specific therapies are lacking. Significant knowledge gaps in IMDP pathogenesis still exist, e.g. precise antigen(s) and mechanisms that initially trigger immune system activation and identification of large population disease susceptibility factors. The initial directional cues for antigen-specific effector or autoreactive leukocyte trafficking into peripheral nerves are also unknown. An overview of current animal models, with emphasis on the experimental autoimmune neuritis and spontaneous autoimmune peripheral polyneuropathy models, is provided. Insights on the initial directional cues for peripheral nerve tissue specific autoimmunity using a novel Major Histocompatibility Complex class II conditional knockout mouse strain are also discussed, suggesting an essential research tool to study cell- and time-dependent adaptive immunity in autoimmune diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. An atypical case of pure motor neuropathy with proximal limb weakness and polyphasic course.
- Author
-
Kelly, Conor W., Lacomis, David, and Al‐Lahham, Tawfiq
- Subjects
- *
MOTOR neuron diseases , *POLYNEUROPATHIES , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *MOTOR unit , *NERVE conduction studies - Abstract
This article explores a unique case of pure motor neuropathy with proximal limb weakness and a polyphasic course. The patient experienced progressive weakness in their legs, arms, and hands, eventually leading to the inability to walk unassisted. Laboratory studies revealed elevated levels of serum anti-ganglioside-GM1 immunoglobulin-M (IgM) and mild cerebrospinal fluid protein elevation. The patient underwent treatment with intravenous methylprednisolone, intravenous immunoglobulin, and rituximab, resulting in improved strength after two years, although some residual weakness remained. The article highlights the challenges in distinguishing between multifocal motor neuropathy (MMN) and motor chronic inflammatory demyelinating polyradiculoneuropathy (motor-CIDP), suggesting that certain cases of motor-CIDP may represent a symmetric variant of MMN. The authors stress the importance of further research to enhance understanding and classification of these conditions, as misdiagnosis can lead to inappropriate treatment. The authors disclose no conflicts of interest, and the data is available upon request. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
31. Recurrent CNTN1 antibody-positive nodopathy: a case report and literature review.
- Author
-
Min Zhao, Guixian Chen, Shuguang Li, Xiaojun Li, Haoxuan Chen, Zhenzhen Lou, Huiying Ouyan, Yibo Zhan, Chenghao Du, and Yuanqi Zhao
- Subjects
LITERATURE reviews ,CHRONIC inflammatory demyelinating polyradiculoneuropathy ,ESSENTIAL tremor ,CEREBROSPINAL fluid ,TREMOR - Abstract
Background: Contactin-1 (CNTN1) antibody-positive nodopathy is rare and exhibits distinct clinical symptoms such as tremors and ataxia. However, the mechanisms of these symptoms and the characteristics of the cerebral spinal fluid (CSF) remain unknown. Case presentation: Here, we report a case of recurrent CNTN1 antibody-positive nodopathy. Initially, a 45-year-old woman experiencing numbness in the upper limbs and weakness in the lower limbs was diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Eleven years later, her symptoms worsened, and she began to experience tremors and ataxia. Tests for serum CNTN1, GT1a, and GQ1b antibodies returned positive. Subsequently, she was diagnosed with CNTN1 antibody-positive nodopathy and underwent plasmapheresis therapy, although the treatment's efficacy was limited. To gain a deeper understanding of the disease, we conducted a comprehensive literature review, identifying 52 cases of CNTN1 antibody-positive nodopathy to date, with a tremor prevalence of 26.9%. Additionally, we found that the average CSF protein level in CNTN1 antibody-positive nodopathy was 2.57 g/L, with 87% of patients exhibiting a CSF protein level above 1.5 g/L. Conclusion: We present a rare case of recurrent CNTN1 antibody-positive nodopathy. Our findings indicate a high prevalence of tremor (26.9%) and elevated CSF protein levels among patients with CNTN1 antibody-positive nodopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review.
- Author
-
Cutellè, Claudia, De Lorenzo, Alberto, Doneddu, Pietro Emiliano, Creta, Maria Francesca, Selmi, Carlo, Liberatore, Giuseppe, Giordano, Andrea, Gentile, Francesco, Erre, Gian Luca, and Nobile‐Orazio, Eduardo
- Subjects
- *
CHEMOKINES , *MEDICAL information storage & retrieval systems , *GUILLAIN-Barre syndrome , *DESCRIPTIVE statistics , *SYSTEMATIC reviews , *MEDLINE , *NEUROLOGICAL disorders , *INTERFERONS , *POLYNEUROPATHIES , *CYTOKINES , *INFLAMMATION , *MOTOR neuron diseases , *BIOMARKERS , *INTERLEUKINS , *TUMOR necrosis factors - Abstract
Advances in the understanding of cytokines have revolutionized mechanistic treatments for chronic inflammatory and autoimmune diseases, as exemplified by rheumatoid arthritis. We conducted a systematic literature review on the role of cytokines and chemokines in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). Ovid Medline, EMBASE and Web of Science were searched until August 31, 2022 for human studies investigating cytokines levels in CIDP or MMN. Fifty‐five articles on 1061 CIDP patients and 86 MMN patients were included, with a median of 18 patients per study (range 3–71). Studies differed in the inclusion criteria, type of assay, manufacturer, control subjects, and tested biological material. Only a minority of studies reported data on disease activity. Interleukin (IL)‐6, IL‐17, CXCL10, and tumor necrosis factor alpha (TNF‐α), were elevated in CIDP compared to controls in most of the studies. IL‐6 and TNF‐α levels are also correlated with disability. In MMN patients, IL‐1Ra was elevated in the majority of the reports. While acknowledging the challenges in comparing studies and the various limitations of the studies, including small patient numbers, particularly in MMN, our review suggests that IL‐6, IL‐17, CXCL10, and TNF‐α might play a role in CIDP pathogenesis. Larger studies are needed in MMN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. FcRn Inhibitor Therapies in Neurologic Diseases.
- Author
-
Alfaidi, Nouf, Karmastaji, Salama, Matic, Alexandria, and Bril, Vera
- Subjects
- *
NEUROMYELITIS optica , *NEUROLOGICAL disorders , *POLYNEUROPATHIES , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *IMMUNOGLOBULIN M , *IMMUNOGLOBULIN E , *MYELIN oligodendrocyte glycoprotein , *IMMUNOGLOBULIN G , *MONOCLONAL antibodies - Abstract
In the last decade, the landscape of treating autoimmune diseases has evolved with the emergence and approval of novel targeted therapies. Several new biological agents offer selective and target-specific immunotherapy and therefore fewer side effects, such as neonatal Fc receptor (FcRn)-targeting therapy. Neonatal Fc receptor-targeted therapies are engineered to selectively target FcRn through various methods, such as Fc fragments or monoclonal anti-FcRn antibodies. These approaches enhance the breakdown of autoantibodies by blocking the immunoglobulin G recycling pathway. This mechanism reduces overall plasma immunoglobulin levels, including the levels of pathogenic autoantibodies, without affecting the other immunoglobulin class immunoglobulin A, immunoglobulin E, immunoglobulin M, and immunoglobulin D levels. Drugs that inhibit FcRn include efgartigimod, rozanolixizumab, batoclimab, and nipocalimab. These medications can be administered either intravenously or subcutaneously. Numerous clinical trials are currently underway to investigate their effectiveness, safety, and tolerability in various neurological conditions, including myasthenia gravis and other neurological disorders such as chronic inflammatory demyelinating polyneuropathy, myositis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. Positive results from clinical trials of efgartigimod and rozanolixizumab led to their approval for the treatment of generalized myasthenia gravis. Additional clinical trials are still ongoing. Neonatal Fc receptor inhibitor agents seem to be well tolerated. Reported adverse events include headache (most commonly observed with efgartigimod and rozanolixizumab), upper respiratory tract infection, urinary tract infection, diarrhea, pyrexia, and nausea. Additionally, some of these agents may cause transient hypoalbuminemia and hypercholesterolemia notably reported with batoclimab and nipocalimab. In this review, we discuss the available clinical data for FcRN inhibitor agents in treating different neurological autoimmune diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Neurophysiological and Ultrasound Correlations in Guillain Barré Syndrome and CIDP—Case Series.
- Author
-
Pigońska, Justyna, Paweł, Walkowiak, and Banach, Marta
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *SPINAL nerve roots , *PERIPHERAL nervous system , *ULTRASONIC imaging , *GUILLAIN-Barre syndrome - Abstract
Introduction: Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are inflammatory polyneuropathies with an autoimmune etiology. These diseases differ mainly in the timing of their course but also in certain clinical differences. Electroneurography and electromyography are crucial for fulfilling the primary (for CIDP) and secondary (for GBS) diagnostic criteria. High-resolution ultrasound (HRUS) is recognized as a complementary method in the diagnosis of CIDP and GBS. Aim: The aim of this study was to present the neurophysiological and ultrasound findings of patients with clinically diagnosed inflammatory neuropathies (GBS and CIDP). Material and Methods: We collected data from clinically confirmed patients with GBS (3 persons) and CIDP (6 persons). The neurography and high-resolution ultrasound examinations according to the UPSS scale were performed. Results: The neurography tests of GBS and CIDP patients showed mainly demyelinating lesions of the examined nerves, often with abnormal F-wave recordings. Examination using HRUS in GBS patients showed mild and regional nerve swelling with hypoechoic bundles with a predilection for proximal segments and cervical spinal nerve roots. In contrast, CIDP patients had diffused nerve swelling with hypoechoic bundles of greater severity and extent than those with GBS. Conclusion: Neurophysiological tests and HRUS of peripheral nerves, plexi, and roots performed together can be very valuable, complementary diagnostic methods for the early diagnosis and effective treatment of inflammatory polyneuropathies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Response to therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy: An observational study.
- Author
-
Gupta, Salil, Singh, Sindhu, Dhull, Pawan, Anadure, Ravi, Somashekharan, Manoj, and Sreen, Amit
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *POLYNEUROPATHIES , *SCIENTIFIC observation , *INTRAVENOUS immunoglobulins - Abstract
Background & Objective: The existing practice in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is to initiate therapy with steroids, intravenous immune globulin (IVIg), or plasma exchange (PLEX) followed by period of immunosuppression. The objective of this study is to assess disability outcomes at 6 months after starting therapy. Methods: Patients who were diagnosed as having CIDP from the Army Hospital of Research and Referral, Delhi; who were initiated and maintained on therapy by treating neurologists with a six month follow up were included in this study. They were retrospectively divided into three groups based on initial therapy received. The primary outcome was comparison of the Inflammatory Neuropathy Cause and Treatment (INCAT) group overall disability sum score (INCAT-ODSS) at 6 months. Secondary outcomes were difference in score at 1 and 3 months, proportion with at least 20% response at 3 and 6 months ("responders") and proportion who needed "rescue" therapy during the 6 months. Results: Sixty patients (26 retrospective, 34 prospective) were included in this study. They were treated with IVIg (33), steroid (19) and PLEX (8). Baseline INCAT-ODSS score (±SD) was 7.2(2.2), 7.2(1.5) and 7.5(1.9) respectively. All received some form of oral immune suppression during follow up. Twenty one (35%) needed additional rescue therapy. There was an overall significant reduction in the mean INCAT-ODSS disability score from 7.2 to 3.1 (Mean difference 4.2; CI 3.6-4.8); p<0.01). Nearly 88% of patients (51/58) showed at least 20% improvement from baseline. Two were lost to follow up (1 IVIg, 1 steroid). There was no difference in the ODSS at 6 months [2.9(2.4), 3.5(2.7) and 2.7(1.3)] respectively. No difference in ODSS at 1 and 3 months. Proportion of responders at 6 months and proportion who needed rescue therapy were also similar. Conclusion: Irrespective of initial therapy and maintenance oral immunosuppression used, the overall disability reduction in treatment with IVIg, steroid or PLEX is significant; however the three modalities are comparable in terms of disability reduction at 6 months. At least a third may need additional rescue therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Oral Presentations.
- Subjects
- *
EPILEPSY , *CLUSTER headache , *MEDICAL personnel , *SEIZURES (Medicine) , *DIFFUSION magnetic resonance imaging , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NEUROLOGICAL disorders - Abstract
This document provides concise summaries of several research studies on neurological conditions. The studies cover a wide range of topics, including the association between distressing dreams and cognitive decline, family history patterns in Alzheimer's disease patients, the role of the orexin system in post-traumatic stress disorder, the significance of plasma p-tau217 in predicting dementia risk, autonomic dysfunction in REM sleep behavior disorder and its implications for Parkinson's disease, NLRP3-inflammasome inhibition in reducing stroke-induced inflammation, and the safety and efficacy of antiplatelet regimens in carotid stenting. These studies offer valuable insights into the understanding and potential treatment of neurological disorders. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
37. Anti‐TNF‐α drug‐induced lupus presenting with cutaneous vasculitis and mononeuritis multiplex.
- Author
-
Jeries, Helana, Hassan, Fadi, Khoury, Wasim, Samih, Badarny, and Naffaa, Mohammad E.
- Subjects
- *
POLYNEUROPATHIES , *DRUG side effects , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *VASCULITIS - Abstract
This article presents a case study of a patient with ankylosing spondylitis who developed a severe neurological condition called mononeuritis multiplex after receiving infliximab treatment. The patient also experienced a skin rash and had positive antibodies. The article discusses the adverse effects of anti-TNF-α drugs and emphasizes the importance of early recognition and management of these complications. Additionally, the article presents three cases of mononeuritis multiplex in patients receiving TNFi treatment, highlighting the need to consider potential neurological side effects. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
38. Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study.
- Author
-
Cocito, Dario, Peci, Erdita, Torrieri, Maria Claudia, and Clerico, Marinella
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NEURALGIA , *PROOF of concept , *CHRONIC pain , *PAIN management - Abstract
Background/Objectives: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease. Neuropathic pain (NP), related to peripheral inflammation, is among its earliest manifestations. This preliminary open-label investigation aimed to evaluate the efficacy of ultramicronized Palmitoylethanolamide (umPEA) in the management of NP. Methods: A total of 14 patients with CIDP, already undergoing immunoglobulin (Ig) therapy, were divided into two groups: Group A received umPEA 600 mg twice daily in addition to Ig for 60 days, followed by Ig alone until the end of the observation (180 days); Group B received Ig alone for 120 days and subsequently umPEA + Ig in the last 60 days of the study. Painful symptom intensity and quality of life were assessed by the Numeric Rating Scale, Neuropathic Pain Symptoms Inventory, and Five Dimensions Health Questionnaire. The safety umPEA profile was evaluated. Results: UmPEA in addition to immunoglobulins allowed for a significant improvement over time in all NP symptoms intensity (p = 0.0007) and in patients' quality of life (p = 0.0036). Conclusions: This study suggests umPEA as a safe and effective treatment in addition to immunoglobulins to improve NP, ameliorating the patient's health status. These results highlight the importance of neuroinflammation modulation in the management of CIDP's painful symptoms, drawing attention to umPEA's potential use also in neuropathies of different etiologies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Clinical characteristics of patients with autoimmune nodopathy with antineurofascin155 antibodies.
- Author
-
Jiwei Zhang, Xiaotong Hou, Liting Wei, Jinshun Liu, Shibo Li, Yifan Guo, Hongbo Liu, and Yan Jiang
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,IMMUNOGLOBULINS ,CEREBROSPINAL fluid - Abstract
Background: According to the latest guidelines on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), patients with CIDP with antineurofascin 155 (NF155) antibodies are referred to as autoimmune nodopathy (AN), an autoimmune disorder distinct from CIDP. We aimed to compare the clinical data of patients with AN with anti-NF155 antibodies with those of antiNF155 antibodies-negative patients with CIDP, and to summarize the clinical characteristics of patients with AN with anti-NF155 antibodies. Methods: Nine patients with AN with anti-NF155 antibodies and 28 serologically negative patients with CIDP were included in this study. Diagnosis was made according to the diagnostic criteria in the European Academy of Neurology (EAN)/ Peripheral Nerve Society (PNS) guidelines on CIDP published in 2021. Demographics, clinical manifestations, electrophysiological examination, cerebrospinal fluid (CSF) tests, and response to treatment were retrospectively analyzed. Results: Compared with serologically negative patients with CIDP, those patients with AN with anti-NF155 antibodies were younger (p=0.007), had a younger onset age (p=0.009), more frequent ataxia (p=0.019), higher CSF protein levels (p=0.001), and more frequent axon damage in electrophysiology (p=0.025). The main characteristics of patients with AN with anti-NF155 antibodies include younger age and onset age, limb weakness, sensory disturbance, ataxia, multiple motor−sensory peripheral neuropathies with demyelination and axonal damage on electrophysiological examination, markedly elevated CSF protein levels, and varying degrees of response to immunotherapy. Conclusions: Patients with AN with anti-NF155 antibodies differed from serologically negative patients with CIDP in terms of clinical characteristics. When AN is suspected, testing for antibodies associated with the nodes of Ranvier is essential for early diagnosis and to guide treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. 14th International Congress on Autoimmunity.
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *AUTOIMMUNE diseases , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *AUTOIMMUNITY , *MEDICAL personnel , *TYPE 1 diabetes , *STILL'S disease - Abstract
The European Journal of Rheumatology is an open access journal that covers various aspects of rheumatology. It publishes original articles, reviews, case-based reviews, and letters to the editor. The journal is aimed at academicians, practitioners, specialists, and students in the field of rheumatology. The document provides a schedule of sessions and presentations at a conference on autoimmune diseases, covering topics such as COVID-19, lupus, vasculitis, and novel approaches to handling autoimmune diseases. It also contains summaries of presentations on topics related to autoimmune diseases, including myositis, post-COVID syndrome, uveitis, and genetic predisposition to autoimmunity. The document discusses cell therapy, novel therapies, and the impact of environmental factors on autoimmune diseases. It explores the potential of CAR-T cell therapy, mesenchymal stromal cell transplantation, cannabis, therapeutic peptides, and RNA gene expression in the treatment and management of autoimmune diseases. The document also highlights the impact of COVID-19 on patients with systemic lupus erythematosus (SLE), finding that SLE patients have an increased risk of severe COVID-19 and higher mortality rates. The document contains summaries of various research studies and discussions related to autoimmune diseases, covering topics such as inflammatory signals in myeloid cells, cardiovascular risk profile of rheumatoid arthritis patients, and immunonutritional status of patients with systemic lupus erythematosus. It also explores subjects such as autoantib [Extracted from the article]
- Published
- 2024
41. Autoimmune nodopathy.
- Author
-
Iijima, Masahiro
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *NERVE conduction studies , *AUTOIMMUNE diseases , *CRANIAL nerves , *CEREBROSPINAL fluid , *TREMOR , *MOLECULAR structure - Abstract
Autoimmune nodopathy (AN) is characterized by the presence of autoantibodies targeting molecules essential for saltatory conduction in myelinated nerves. Clinical manifestations of AN show similarities with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including progressive and symmetrical sensorimotor deficits with electrophysiological demyelinating features in nerve conduction studies. Although no common autoantibodies have yet been identified in CIDP, AN is characterized by autoantibodies that primarily target specific molecular complex structures represented by the Ranvier node and paranode. Furthermore, these autoantibodies, such as neurofascin‐155 (NF155), contactin‐1 (CNTN1), contactin‐related protein 1 (Caspr1), and the CNTN1/Caspr1 complex, are illustrative examples of such autoantibodies. They can disrupt the septal‐like junction of paranodes without triggering cellular immune responses. AN manifests uniquely with symptoms such as ataxia, tremors, and markedly high cerebrospinal fluid (CSF) protein levels, often accompanied by nerve root and cranial nerve hypertrophy. Notably, this condition is resistant to immunotherapies typically effective against CIDP, including intravenous immunoglobulin therapy (IVIg). Current evidence suggests that B‐cell depletion therapies, such as rituximab, could benefit AN treatment. Since it has been suggested that existing treatments for CIDP may be effective in cases of autoantibody positivity of subclasses other than IgG4, CIDP that is resistant to conventional therapy requires novel therapeutic strategies that take into account the possibility of IgG4 autoantibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Therapeutic progress and future prospects of chronic inflammatory demyelinating polyradiculoneuropathy.
- Author
-
Okamoto, Tomoko
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *REMISSION induction , *PERIPHERAL nervous system - Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune‐mediated neuropathy. The pathogenesis of CIDP is complex interplay of diverse immune mechanisms involving cellular and humoral pathways. The European Academy of Neurology/Peripheral Nerve Society guidelines were reissued in 2021, and the classification and diagnostic criteria were changed. Treatments include immunoglobulin, steroid, and plasmapheresis are effective, including remission induction and maintenance therapy. Maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. In this review, the new guidelines, treatment recommendations based on guidelines and expert opinion, and future treatments including anti CD20 monoclonal antibody, FcRn blocker, and Cs1 inhibitor are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. A study on the role of serum uric acid in differentiating acute inflammatory demyelinating polyneuropathy from acute‐onset chronic inflammatory demyelinating polyneuropathy.
- Author
-
Zhang, Weiyun, Tao, Wen, Wang, Jun, Nie, Ping, Duan, Lihui, and Yan, Lanyun
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *POLYNEUROPATHIES , *URIC acid , *GUILLAIN-Barre syndrome , *MOTOR neuron diseases , *RECEIVER operating characteristic curves - Abstract
Background and purpose: Clinical symptoms and laboratory indices for acute inflammatory demyelinating polyneuropathy (AIDP), a variant of Guillain−Barré syndrome, and acute‐onset chronic inflammatory demyelinating polyneuropathy (A‐CIDP) were analyzed to identify factors that could contribute to early differential diagnosis. Methods: A retrospective chart review was performed on 44 AIDP and 44 A‐CIDP patients looking for any demographic characteristics, clinical manifestations or laboratory parameters that might differentiate AIDP from acutely presenting CIDP. Results: In Guillain−Barré syndrome patients (N = 63), 69.84% (N = 44) were classified as having AIDP, 19.05% (N = 12) were found to have acute motor axonal neuropathy, 6.35% (N = 4) were found to have acute motor and sensory axonal neuropathy, and 4.76% (N = 3) were found to have Miller Fisher syndrome. Serum uric acid (UA) was higher in A‐CIDP patients (329.55 ± 72.23 μmol/L) than in AIDP patients (221.08 ± 71.32 μmol/L) (p = 0.000). Receiver operating characteristic analyses indicated that the optimal UA cutoff was 283.50 μmol/L. Above this level, patients were more likely to present A‐CIDP than AIDP (specificity 81.80%, sensitivity 81.80%). During the follow‐up process, serum samples were effectively collected from 19 AIDP patients during the rehabilitation phase and 28 A‐CIDP patients during the remission stage, and it was found that UA levels were significantly increased in A‐CIDP (remission) (298.9 ± 90.39 μmol/L) compared with AIDP (rehabilitation) (220.1 ± 108.2 μmol/L, p = 0.009). Conclusion: These results suggest that serum UA level can help to differentiate AIDP from A‐CIDP with high specificity and sensitivity, which is helpful for early diagnosis and guidance of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review.
- Author
-
Verona, Paige, Edwards, Jocelyn, Hubert, Kassidy, Avorio, Federica, Re, Vincenzina Lo, Di Stefano, Roberta, Carollo, Anna, Johnson, Heather, and Provenzani, Alessio
- Subjects
- *
LITERATURE reviews , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *POSTERIOR leukoencephalopathy syndrome , *NEUROTOXICOLOGY - Abstract
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used globally to prevent rejection after organ transplantation. Although it significantly improves outcomes for solid organ transplant patients, it is associated with various side effects such as nephrotoxicity and neurotoxicity. Tacrolimus-induced neurotoxicity is frequently encountered in clinical practice and can present with a variety of symptoms that may occur even at therapeutic levels. Although tacrolimus-induced neurotoxicity is well documented, there is limited literature available on pharmacologic management. Twenty-eight case reports of tacrolimus-induced neurotoxicity were identified and analyzed in addition to other literature including reviews, retrospective studies, and animal model studies. The severity of cases of tacrolimus-induced neurotoxicity reported ranged from mild symptoms that could be managed with symptomatic treatment to conditions such as posterior reversible encephalopathy syndrome and chronic inflammatory demyelinating polyradiculoneuropathy that may require more immediate intervention. This information was utilized in addition to clinical experience to compile potential management options for prevention and treatment of neurotoxic adverse events. This review is limited by the utilization of primarily retrospective studies and case reports. The available literature on the subject is largely narrative and there are no guidelines on treatment of tacrolimus-induced neurotoxicity at the time of this research. This comprehensive review may guide further studies to investigate the pathophysiology of tacrolimus-induced neurotoxicity and to define patient-specific strategies for mitigation or minimization of neurotoxicity. This is especially important given that management of tacrolimus-induced neurotoxicity can include changes to immunosuppression that can result in an increased risk of rejection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Inflammatory neuropathy with evidence of anti-GQ1b antibodies in angioimmunoblastic T cell lymphoma (AITL): a case report.
- Author
-
Kleeberg, Antonia, Bauer, Gregor, Jung, Erik, and Purrucker, Jan C.
- Subjects
- *
POLYNEUROPATHIES , *T cells , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *CEREBROSPINAL fluid , *DIFFUSE large B-cell lymphomas , *IMMUNOGLOBULINS - Abstract
This article is a case report published in the Journal of Neurology. It describes the medical history and clinical findings of a 66-year-old male patient who was suspected of having Guillain-Barré syndrome (GBS). The patient had rapidly progressive tetraparesis, leg pareses, and urinary and fecal incontinence. The patient had a previous diagnosis of angioimmunoblastic T cell lymphoma (AITL) and had received chemotherapy. The article discusses the diagnostic procedures, therapy, and further course of the patient's condition. The authors highlight the complexity of diagnosing polyneuropathy in lymphoma patients and the importance of considering AITL in autoimmune phenomena. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
46. Gait Assessment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
- Author
-
Llauradó, Arnau, Quintana, Manuel, Gratacós-Viñola, Margarita, Vidal-Taboada, Jose Manuel, Restrepo-Vera, Juan Luis, Alemañ, José, López-Diego, Verónica, Salvadó, Maria, Sanchez-Tejerina, Daniel, Sotoca, Javier, Raguer, Núria, and Juntas-Morales, Raul
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *POLYNEUROPATHIES , *STATISTICAL correlation - Abstract
Background and Aims. Gait impairment is a common manifestation of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). However, clinicians lack an effective monitoring tool, as no gait test has been validated for CIDP. The aim of this study was to determine the usefulness of three tests in monitoring the clinical course of patients with CIDP: Timed Up and Go (TUG), 10-Meter Walk Test (10MWT), and 30-Second Chair Stand (30SCS). Methods. This is a prospective, single-center observational study. We included newly diagnosed CIDP patients starting treatment or relapsed CIDP patients requiring new treatment. We monitored the clinical course using CIDP-validated clinical scales and correlated changes in clinical status with the results of the gait tests. A ROC curve was developed, and we chose the cut-off point on each scale with the best specificity and sensitivity to detect change in clinical status. Results. A total of 20 patients have been recruited. The 3 tests show a statistical correlation with objective clinical improvement. In patients who have showed clinical improvement during the follow-up examination, a mean reduction of 4.8 seconds in TUG and 2.6 in 10MWT and a gain of 3 repetitions in 30SCS have been observed. The optimal cut-off points for each test were TUG ≤ 1 seconds, 10 MWT ≤ 1 seconds, and 30 SCS ≥ 1 repetition. The TUG test has the highest sensitivity (82.6%), and the 30SCS test has the highest specificity (100%) for detecting clinical improvement. Conclusions. The study found that the TUG and 30SCS tests could become effective tools for monitoring treatment response in CIDP patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Neuromuscular ultrasound in combination with nerve conduction studies helps identify inflammatory motor neuropathies from lower motor neuron syndromes.
- Author
-
Zhang, Lei, Li, Yi, Niu, Jingwen, Hu, Nan, Ding, Jianfeng, Cui, Liying, and Liu, Mingsheng
- Subjects
- *
POLYNEUROPATHIES , *NERVE conduction studies , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *MOTOR neurons , *AMYOTROPHIC lateral sclerosis , *MOTOR neuron diseases - Abstract
Background and purpose: Identifying patients with inflammatory motor neuropathies (IMNs) is warranted since effective treatments are available and the prognosis of these patients differs from that of amyotrophic lateral sclerosis patients. Methods: Between January 2019 and May 2022, 102 consecutive treatment‐naïve lower motor neuron syndrome (LMNS) patients were recruited; these patients were suspected of having multifocal motor neuropathy, pure motor chronic inflammatory demyelinating polyneuropathy or amyotrophic lateral sclerosis with initial lower motor neuron presentation. Neuromuscular ultrasound (US) and nerve conduction studies (NCSs) were conducted at baseline. Relevant diagnostic investigations were performed if clinically warranted. The proposed US evidence of IMN was as follows: (i) nerve enlargement at ≥1 of the predetermined sites or (ii) absence of high intensity fasciculations in predefined muscle groups. Final diagnoses were made by experienced physicians after a prolonged follow‐up period (≥12 months). IMN patients were defined as LMNS patients who experienced convincing improvements in response to immunotherapies. IMN patients without electrodiagnostic demyelinating features were diagnosed with treatment‐responsive LMNS (TR‐LMNS). Results: In total, 16 patients were classified as IMN, including nine chronic inflammatory demyelinating polyneuropathy/multifocal motor neuropathy patients and seven TR‐LMNS patients. Six TR‐LMNS patients were identified by neuromuscular US. The sensitivity and specificity of NCSs, nerve US and muscle US were 56.3% and 100%, 43.8% and 90.7% and 68.8% and 97.7%, respectively. When these three modalities were combined, the sensitivity and specificity were 93.8% and 88.4%, respectively. Conclusion: Neuromuscular US studies are supplementary modalities to NCSs, and the combined use of these techniques might improve the identification of IMNs in LMNS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy.
- Author
-
Fisse, Anna Lena, Schäfer, Emelie, Hieke, Alina, Schröder, Maximilian, Klimas, Rafael, Brünger, Jil, Huckemann, Sophie, Grüter, Thomas, Sgodzai, Melissa, Schneider‐Gold, Christiane, Gold, Ralf, Nguyen, Huu Phuc, Pitarokoili, Kalliopi, Motte, Jeremias, and Arning, Larissa
- Subjects
- *
POLYNEUROPATHIES , *CHRONIC inflammatory demyelinating polyradiculoneuropathy , *TANDEM repeats , *FC receptors , *GENE expression , *INTRAVENOUS immunoglobulins - Abstract
Background and purpose: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease with humoral and cellular autoimmunity causing demyelination of peripheral nerves, commonly treated with intravenous immunoglobulins (IVIg). The neonatal Fc receptor (FcRn), encoded by the FCGRT gene, prevents the degradation of immunoglobulin G (IgG) by recycling circulating IgG. A variable number of tandem repeat (VNTR) polymorphism in the promoter region of the FCGRT gene is associated with different expression levels of mRNA and protein. Thus, patients with genotypes associated with relatively low FcRn expression may show a poorer treatment response to IVIg due to increased IVIg degradation. Methods: VNTR genotypes were analyzed in 144 patients with CIDP. Patients' clinical data, including neurological scores and treatment data, were collected as part of the Immune‐Mediated Neuropathies Biobank registry. Results: Most patients (n = 124, 86%) were VNTR 3/3 homozygotes, and 20 patients (14%) were VNTR 2/3 heterozygotes. Both VNTR 3/3 and VNTR 2/3 genotype groups showed no difference in clinical disability and immunoglobulin dosage. However, patients with a VNTR 2 allele were more likely to receive subcutaneous immunoglobulins (SCIg) than patients homozygous for the VNTR 3 allele (25% vs. 9.7%, p = 0.02) and were more likely to receive second‐line therapy (75% vs. 54%, p = 0.05). Conclusions: The VNTR 2/3 genotype is associated with the administration of SCIg, possibly reflecting a greater benefit from SCIg due to more constant immunoglobulin levels without lower IVIg levels between the treatment circles. Also, the greater need for second‐line treatment in VNTR 2/3 patients could be an indirect sign of a lower response to immunoglobulins. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.
- Author
-
De Lorenzo, Alberto, Liberatore, Giuseppe, Doneddu, Pietro Emiliano, Manganelli, Fiore, Cocito, Dario, Briani, Chiara, Fazio, Raffaella, Mazzeo, Anna, Schenone, Angelo, Di Stefano, Vincenzo, Cosentino, Giuseppe, Marfia, Girolama Alessandra, Benedetti, Luana, Carpo, Marinella, Filosto, Massimiliano, Antonini, Giovanni, Clerici, Angelo Maurizio, Luigetti, Marco, Matà, Sabrina, and Rosso, Tiziana
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *PERIPHERAL nervous system , *POLYNEUROPATHIES , *ACTION potentials - Abstract
Background and purpose: There are different criteria for the diagnosis of different variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guidelines provide specific clinical criteria for each CIDP variant even if their therapeutical impact has not been investigated. Methods: We applied the clinical criteria for CIDP variants of the 2021 EAN/PNS guidelines to 369 patients included in the Italian CIDP database who fulfilled the 2021 EAN/PNS electrodiagnostic criteria for CIDP. Results: According to the 2021 EAN/PNS clinical criteria, 245 patients achieved a clinical diagnosis of typical CIDP or CIDP variant (66%). We identified 106 patients with typical CIDP (29%), 62 distal CIDP (17%), 28 multifocal or focal CIDP (7%), four sensory CIDP (1%), 27 sensory‐predominant CIDP (7%), 10 motor CIDP (3%), and eight motor‐predominant CIDP (2%). Patients with multifocal, distal, and sensory CIDP had milder impairment and symptoms. Patients with multifocal CIDP had less frequently reduced conduction velocity and prolonged F‐wave latency and had lower levels of cerebrospinal fluid protein. Patients with distal CIDP more frequently had reduced distal compound muscle action potentials. Patients with motor CIDP did not improve after steroid therapy, whereas those with motor‐predominant CIDP did. None of the patients with sensory CIDP responded to steroids, whereas most of those with sensory‐predominant CIDP did. Conclusions: The 2021 EAN/PNS criteria for CIDP allow a better characterization of CIDP variants, permitting their distinction from typical CIDP and more appropriate treatment for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Evaluation of diagnostic yield of the 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria for CIDP.
- Author
-
Kanbayashi, Takamichi, Hokkoku, Keiichi, Tachiyama, Keisuke, Hatanaka, Yuki, and Sonoo, Masahiro
- Abstract
Introduction/Aims: It is unclear whether the revised European Academy of Neurology/Peripheral Nerve Society diagnostic criteria (EAN/PNS 2021 criteria) improved the diagnostic yield for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) compared with the previous version. Therefore, this study aimed to compare the sensitivity and specificity of the EAN/PNS 2021 criteria and the European Federation of Neurological Societies/Peripheral Nerve Society 2010 diagnostic criteria (EFNS/PNS 2010 criteria), with a specific focus on the electrodiagnostic criteria. Methods: Data of patients with clinically suspected CIDP who exhibited objective treatment response, and of those with chronic axonal neuropathies, obtained between 2009 and 2021, were extracted retrospectively from our database. Patients who underwent nerve conduction studies in at least unilateral upper and lower extremities were enrolled. We compared the sensitivity and specificity of the EAN/PNS 2021 and EFNS/PNS 2010 criteria. Results: In total, 55 patients with clinically suspected CIDP and 36 patients with chronic axonal neuropathies were enrolled. When considering the "possible CIDP" category, the EAN/PNS 2021 criteria showed lower sensitivity than the EFNS/PNS 2010 criteria (78% vs. 93%, p <.05), whereas its specificity was higher (78% vs. 61%, p <.05). The lower sensitivity was caused mainly by the failure to fulfill the sensory nerve conduction criteria. The revised definition of abnormal temporal dispersion of the tibial nerve contributed markedly to the improved specificity. Discussion: To improve the sensitivity of the EAN/PNS 2021 criteria, increasing the number of tested sensory nerves may be necessary. See Editorial on pages 387–388 in this issue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.